Company intelligence / Profile preview
Iktos
- Ownership
- Private
- Development stage
- Preclinical
Overview
Iktos has developed a proprietary generative AI-driven drug discovery platform that integrates molecular design, automated synthesis robotics, and high-throughput biological testing. Their in-house pipeline includes preclinical candidates targeting inflammation/autoimmune diseases, oncology, obesity/metabolism disorders, and immuno-oncology. The company claims the ability to deliver preclinical candidates in less than two years using their integrated DMTA cycle. Lead programs are currently at the preclinical candidate nomination stage; no clinical results have been reported yet.
- Therapeutic areas
- OncologyMetabolic DisordersImmunology
- Modalities
- Small molecule
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Iktos.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Iktos.